Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
NCT06474663 · M.D. Anderson Cancer Center · PHASE1 · withdrawn · last registry update 2025-08-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “0 participants” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RAF1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-28Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-M07D1 + Regorafenib (NCT07730489)
- 2026-07-23Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., IBI363 + bevacizumab + Investigator's choice of therapy (NCT07722494)
- 2026-07-22Results posted on the registry: Amgen, Sotorasib + Panitumumab (NCT05198934)
- 2026-07-20Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against RAF1 (NCT07712848)
- 2026-07-20Results posted on the registry: Academic and Community Cancer Research United, Durvalumab + Regorafenib (NCT05194293)
- 2026-07-14Results posted on the registry: Jennerex Biotherapeutics, JX-594 + Sorafenib (NCT01171651)
- 2026-07-08Results posted on the registry: Jennerex Biotherapeutics, JX-594 recombinant vaccina GM-CSF (NCT01387555)
- 2026-07-06Results posted on the registry: Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-07-06Also stopped (terminated): Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-06-16Results posted on the registry: University of Southern California, Pembrolizumab + Regorafenib (NCT03657641)
- 2026-06-15Also stopped (withdrawn): University of Miami, Regorafenib (NCT06902246)
- 2026-06-10Results posted on the registry: Australasian Gastro-Intestinal Trials Group, Regorafenib + Nivolumab (NCT04879368)
- 2026-03-30Results posted on the registry: HonorHealth Research Institute, Vemurafenib + Sorafenib (NCT05068752)
- 2026-03-19Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., TQB2102 Injection + Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets (NCT07483684)
- 2026-03-11Phase 3 first posted: The First Affiliated Hospital of Soochow University, Gilteritinib + Sorafenib (NCT07463651)
- 2026-03-11Also stopped (withdrawn): M.D. Anderson Cancer Center, Regorafenib + Lorigerlimab (NCT07137390)
- 2026-03-09Also stopped (terminated): Translational Research in Oncology, Regorafenib in combination with pembrolizumab (NCT04777851)
- 2026-03-05Results posted on the registry: Wake Forest University Health Sciences, Regorafenib (NCT04327700)
- 2026-03-05Also stopped (terminated): Wake Forest University Health Sciences, Regorafenib (NCT04327700)
- 2026-02-25Also stopped (withdrawn): M.D. Anderson Cancer Center, Regorafenib + Lorigerlimab (NCT07223567)
- 2026-02-23Phase 3 first posted: European Organisation for Research and Treatment of Cancer - EORTC, Gilteritinib + Venetoclax (NCT07425808)
- 2026-02-06Phase 3 first posted: Nanjing Sanhome Pharmaceutical, Co., Ltd., SH006 + Bevacizumab (NCT07392866)
- 2026-02-03Phase 3 first posted: Shanghai JMT-Bio Inc., JSKN003 + Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib. (NCT07384377)
- 2026-01-30Phase 3 first posted: Ningbo Newbay Technology Development Co., Ltd, NB003 + regorafenib (NCT07379047)
- 2026-01-20Results posted on the registry: Bristol-Myers Squibb, BMS-986288 + Nivolumab (NCT03994601)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision